Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

June 04, 2007 09:00 ET

Miraculins Announces Additional Results From PCSC04 Prostate Cancer Diagnostic Study

In addition to its capacity to diagnose cancer, test shows enhanced ability to detect aggressive prostate cancer

WINNIPEG, MANITOBA--(Marketwire - June 4, 2007) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce further results that indicate its prostate cancer test could be used as a tumor grading test.

In addition to the initial findings of the PCSC04 study, announced on May 26, 2007, the Miraculins panel test was able to distinguish aggressive prostate cancer (cancers with a Gleason grade of 7 or higher) from non-aggressive prostate cancer with a sensitivity and specificity of 92% and 55% respectively. The evidence suggests the test could be used as an additional tool for disease management and could help pathologists diagnose the cancer grade in combination with the Gleason score grading. This new discovery requires further study and validation.

"This discovery has the potential to open up another market application for our test", said Christopher J. Moreau, president and CEO of Miraculins. "Men who are diagnosed with prostate cancer are identified as either having a low grade form of the cancer or the aggressive high grade form. A test that helps distinguish between the two with the greatest possible accuracy is critical to a successful treatment strategy."

About Miraculins Inc.

Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for "common" cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company's B.E.S.T. Platform™ utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.

About Prostate Cancer

Prostate cancer is the most common cancer in Canadian men, affecting one in seven, and the most common non-skin cancer in the United States, affecting one in six men. It is often slow-growing and can be managed successfully if detected early through diagnostic screening.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information